iOnctura
Combinations of iOnctura's roginolisib revert immune suppression in immunotherapy-resistant NSCLC
Late breaking data from ongoing Phase I/II PULMO-01, the first clinical study of conformation-selective PI3Kδ inhibitor roginolisib in…
Company newsroom
iOnctura
1 releases